GlaxoSmithKline has decided to shutter Sirtris Pharmaceutical's office in Cambridge, MA, opting to fully integrate their research work now underway into the giant pharma company's R&D operations.
David Sinclair and his allies believe he has scored a major victory in the controversial--and complex--field of anti-aging science. With a new research paper, the Harvard genetics professor shows how the red wine chemical resveratrol and other compounds directly activate an enzyme called SIRT1, an activity on the target that has been hotly contested.
OvaScience, which is focused on developing fertility treatments based on stem cell discoveries, landed a $37 million Series B round of funding.
Just a few months ago Christoph Westphal's new biotech, Verastem, raised a hefty $32 million Series B round based on the promise of the developer's cancer stem cell technology and a trio of noted
Those sexy "fountain of youth" studies on sirtuins that grabbed headlines around the world and helped spur GlaxoSmithKline to spend $720 million to snap up Sirtris at an early development stage have
After biotech Sirtris' anti-aging science took a shelling in recent years, one of the firm's drugs that mimics the red wine chemical resveratrol showed in a new study that it could extend the average
GlaxoSmithKline is dumping its program for SRT501, a special formulation of resveratrol which the pharma company scooped up in the $720 million buyout of Sirtris in 2008. GSK suspended a Phase IIa
GlaxoSmithKline (NYSE: GSK) has ordered two Sirtris executives--Christoph Westphal and Michelle Dipp--to stop selling a resveratrol dietary supplement based on the drug the two companies have in
Over the past few years resveratrol has emerged as one of the most closely-tracked development programs in biotechnology. GlaxoSmithKline paid $720 million to buy Sirtris Pharmaceuticals back in 2007
Recently, GSK forked over $720 million for Sirtris Pharmaceuticals and Japan's Takeda made an